Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: Pediatr Blood Cancer. 2012 Sep 28;60(2):230–236. doi: 10.1002/pbc.24278

Table IV.

Non-hematologic toxicity for all dose levels1.

Grade 1 Grade 2 Grade 3 Grade 4
Vomiting 9 (30%) 5 (16.7%) 6 (20%) 0
Nausea 11 (36.7%) 6 (20%) 2 (6.7%) 0
Neuropathy; sensory 12 (40%) 3 (10%) 1 (3.3%) 0
Hypophosphatemia 10 (33.3%) 3 (10%) 2 (6.7%) 0
AST, elevated 11 (36.7%) 3 (10%) 0 0
Hypokalemia 11 (36.7%) 0 1 (3.3%) 1 (3.3%)
Fatigue 8 (26.7 %) 4 (13.3%) 0 0
ALT, elevated 11 (36.7%) 0 0 0
Hypoalbuminemia 8 (26.7%) 3 (10%) 0 0
Hypocalcemia 9 (30%) 2 (6.7%) 0 0
Diarrhea 9 (30%) 2 (6.7%) 0 0
Hyperglycemia 7 (23.3%) 3 (10%) 1 (3.3%) 0
Hyponatremia 9 (30%) 0 1 (3.3%) 1 (3.3%)
PTT, elevated 8 (26.7%) 0 0 0
Pain, Headache 6 (20%) 2 (6.7%) 0 0
Alkaline Phosphatase, elevated 6 (20%) 0 0 0
Bicarbonate, low 4 (13.3%) 2 (6.7%) 0 0
Fever without neutropenia 4 (13.3%) 1 (3.3%) 1 (3.3%) 0
Pain, Abdomen 4 (13.3%) 1 (3.3%) 1 (3.3%) 0
Hypotension 3 (10%) 0 1 (3.3%) 0
Dyspnea 1 (3.3%) 1 (3.3%) 1 (3.3%) 0
Hemorrhage, nose 2 (6.7%) 0 1 (3.3%) 0
Dehydration 0 0 1 (3.3%) 0
Febrile Neutropenia 0 0 1 (3.3%) 0
SIADH 0 0 0 1 (3.3%)
1

Grade 1 or 2 toxicities occurring in ≥ 20% of patients. All grade 3 or 4 toxicities.